Moderna: Late-stage COVID-19 vaccine data on track for next month | First vaccine doses may be deployed by year-end | Takeda to handle importation of Moderna's COVID-19 vaccine
October 30, 2020
Bio SmartBrief
SIGN UP ⋅   SHARE
Today's Top Story
Moderna said Thursday that the company is on track to release early data next month from a late-stage trial of its experimental COVID-19 vaccine. "Since we are following the ZIP codes (US geographic areas) and the counties from which these participants come, we have pretty sophisticated models of what to expect, and I think we're on track for those expectations," said Tal Zaks, Moderna's chief medical officer.
Full Story: Reuters (10/29) 
LinkedIn Twitter Facebook Email
Health Care & Policy
National Institute of Allergy and Infectious Diseases Director Anthony Fauci said the US will likely know whether there will be a safe and effective vaccine for COVID-19 "sometime in December," based on projections from leading vaccine makers Moderna and Pfizer. Initial doses of a vaccine, if validated, will likely become available to high-risk Americans by year's end or early 2021, Fauci said.
Full Story: Reuters (10/29) 
LinkedIn Twitter Facebook Email
Company & Financial News
Takeda Pharmaceutical of Japan is reportedly in talks with Moderna for the importation and distribution of 50 million doses of its investigational COVID-19 vaccine. Takeda will handle seeking regulatory approval for mRNA-1273, with supplies to be delivered beginning in the first half of next year.
Full Story: Reuters (10/29) 
LinkedIn Twitter Facebook Email
Enrollment of patients will resume next week for the trial testing the coronavirus vaccine developed by AstraZeneca and the UK's Oxford University being conducted at the University of Wisconsin-Madison. Two shots had already been received by 36 volunteers prior to the study being halted temporarily in September.
Full Story: The Associated Press (10/29) 
LinkedIn Twitter Facebook Email
Novartis has unveiled plans to acquire Vedere Bio for $280 million, which includes an upfront payment of $150 million and the balance to be paid as milestone payments. The purchase will strengthen Novartis' presence in the gene therapy field with access to two early-stage programs to treat blindness-causing diseases such as retinitis pigmentosa.
Full Story: Reuters (10/29) 
LinkedIn Twitter Facebook Email
Sanofi will collaborate with Merck subsidiary MSD to evaluate the preliminary efficacy, pharmacokinetics and safety of the latter's candidate THOR-707 in combination with Keytruda, or pembrolizumab, in patients with various types of cancer.
Full Story: PharmaTimes online (UK) (10/29) 
LinkedIn Twitter Facebook Email
Ag & Environment
The full genome of a variety of miscanthus, a wild perennial grass, has been sequenced by an international bioenergy research team of more than 40 collaborators. A potential biomass source, miscanthus grasses are a renewable alternative to fossil fuels that are petroleum-based.
Full Story: PhysOrg/University of Illinois at Urbana-Champaign (10/29) 
LinkedIn Twitter Facebook Email
The Latest From BIO
WATCH: Biotech Votes 2020
(US Flag)
Biotech Votes 2020 uses your super powers to impact the world. BIO introduces a video by Isabella, the 8-year-old daughter of BIO CEO Dr. Michelle McMurry-Heath. Watch the video.
LinkedIn Twitter Facebook Email
BIO Online Learning offers on-demand online courses to help professionals understand the science, business, and regulatory processes essential to the biotechnology, pharmaceutical, molecular diagnostics, and medical device industries. Browse dozens of online courses in a variety of industry areas including drug manufacturing, biotech basics, drug development, biosafety, and more. Discounts are available for BIO members. Learn more.
LinkedIn Twitter Facebook Email
BIO Business Solutions is the largest cost-savings purchasing program for the biotech industry, operated by BIO. We leverage the purchasing power of the industry to negotiate with top suppliers to secure exceptional savings, favorable terms, and superior service for members. BIO members can participate for no charge as a benefit of their membership and to save on items they need to run a successful biotechnology enterprise. Learn more about how you can save.
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT BIO:
Conferences | Join Bio | Media | Issues | Industry
Sharing BIO SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/bio/?referrerId=eSriBJbAIQ
Tomorrow belongs to those who can hear it coming.
David Bowie,
singer-songwriter, musician, actor
LinkedIn Twitter Facebook Email
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004